This is an investigational study. Axitinib is FDA approved and commercially available for the treatment of advanced kidney cancer. Bosutinib is FDA approved and commercially available for the treatment of CML. It is considered investigational to use axitinib and bosutinib in combination to treat CML. The study doctor can explain how the study drugs are designed to work.